Terminé

Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Collecte de données

Qui peut participer

Arthrite+21

+ Arthrite Rhumatoïde

+ Maladies Auto-immunes

À partir de 4 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Observationnel
Date de début : avril 1999
Voir le détail du protocole

Résumé

Sponsor principalNational Institute of Dental and Craniofacial Research (NIDCR)
Dernière mise à jour : 17 décembre 2019
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 9 avril 1999

Date à laquelle le premier participant a commencé l'étude.

Saliva plays a major role in maintaining oral health and comfort. Saliva is needed to moisten the mouth, to lubricate food for easier swallowing, to protect oral hard and soft tissues, to modulate oral microbial populations, to provide enzymes necessary to begin food breakdown for digestion, and to promote soft tissue repair and oral cleansing. Therefore, salivary dysfunction may result in numerous clinical conditions affecting oral and systemic health, comfort and quality of life. In particular, we will focus on individuals with Sj(SqrRoot)(Delta)gren's syndrome, an autoimmune exocrinopathy that primarily affects the salivary and lacrimal glands. A number of unanswered questions remain concerning salivary involvement in this disorder. These include the rate of progression of secretory dysfunction, and related oral and systemic complications associated with xerostomia in autoimmune and non-autoimmune diseases, and B-cell dysregulation. Also, more precise estimates of the incidence of the lymphoma development are needed. The purpose of this study is :1) to allow careful follow-up of patients with defined salivary gland alterations so that the long term course and effects of Sj(SqrRoot)(Delta)gren's syndrome (SS) on the oral cavity and systemic health in SS may be delineated; 2) to follow the development and progression of B-cell dysregulation in SS; 3) to follow subjects to establish whether those initially manifesting incomplete criteria for SS progress toward fully meeting the criteria.; 4) to refine diagnostic tests for SS, and to determine whether those subjects who meet the criteria for SS continue to do so; and 5) to develop intermediary outcome measures for SS based on long term outcomes (loss of tears and loss of stimulated salivary flow). Patients will return every two years from the baseline visit for a full oral examination, salivary function assessment, clinical laboratory studies, and questionnaires concerning signs and symptoms of salivary gland dysfunction. These individuals will be patients with Sj(SqrRoot)(Delta)gren's syndrome (SS), incomplete SS (patients who have some, but not all of the criteria for SS) or radiation-induced salivary gland hypofunction. We anticipate that many of these patients will also participate in therapeutic trials conducted within the branch.

NCT00001852
Sponsor principalNational Institute of Dental and Craniofacial Research (NIDCR)
Dernière mise à jour : 17 décembre 2019
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

560 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

À partir de 4 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

ArthriteArthrite RhumatoïdeMaladies Auto-immunesMaladies du tissu conjonctifMaladies oculairesMaladies hématologiques et lymphatiquesMaladies du Système ImmunitaireTroubles immunoprolifératifsMaladies des ArticulationsMaladies de l'appareil lacrymalMaladies lymphatiquesTroubles LymphoprolifératifsMaladies stomatognathiquesMaladies de la boucheMaladies musculo-squelettiquesNéoplasmesNéoplasmes par type histologiqueMaladies rhumatismalesSyndromes de l'œil secMaladies de la peau et des tissus conjonctifsLymphomeMaladies des glandes salivairesSyndrome de SjögrenXérostomie

Critères

INCLUSION CRITERIA: Male and female subjects. All subjects will have first participated in screening protocol 84-D-0056 to confirm their diagnosis and assess salivary function. Subjects must have dry mouth symptoms (xerostomia) and a diagnosis of primary or secondary SS, incomplete SS, or radiation-induced salivary gland dysfunction (as determined in protocol 84-D-0056). Diagnostic criteria for SS are the American-European Consensus Group Classification Criteria: For primary Sjogren s syndrome, any 4 of the 6 criteria, must include item IV (Histopathology) or VI (Auto-antibodies) or any 3 of the 4 objective criteria (III, IV, V, VI). For secondary Sjogren s syndrome, must have established connective tissue disease, one symptom (I or II) plus 2 of the 3 objective criteria (III, IV, VI). Ocular symptoms (at least one) Daily persistent dry eyes for greater than 3 months? Recurrent sensation of sand or gravel in the eyes? Use of tear substitutes greater than 3 x/day? Oral symptoms (at least one) Daily feeling of dry Mouth greater than 3 months Recurrent or persistently swollen salivary glands as an adult? Frequently drink liquids to aid in swallowing dry foods? Ocular signs (at least one) Schirmer s test, (without anesthesia) greater than or equal to 5mm/5 minutes Positive vital dye staining (van Bijsterveld greater than or equal to 4) Histopathology: Lip biopsy showing focal lymphocytic sialadenitis (focus score greater or equal to 1 per 4mm squared) Oral signs (at least one) Unstimulated whole salivary flow (greater or equal to 1.5 ml in 15 minutes) Abnormal parotid sialography Abnormal salivary scintigraphy Auto-antibodies (at least one) Anti-SSA (Ro) or Anti-SSB (La) EXCLUSION CRITERIA FOR DIAGNOSIS OF SS: Past head and neck radiation treatment Hepatitis C infection Acquired Immunodeficiency Syndrome (AIDS) Pre-existing lymphoma Sarcoidosis Graft versus host disease Current use of anticholinergic drugs EXCLUSION CRITERIA: Failure to complete evaluation procedures as specified in 84-D-0056. Diagnosis of drug-related xerostomia. Age less than 4 years. There are no exclusions based on gender, race, or ethnicity. Salivary gland dysfunction is uncommon in children and exceedingly rare in those less than 4 years old. Additionally, the evaluation method described in the protocol cannot be used in this age group. ULTRASOUND GUIDED CORE NEEDLE BIOPSY OF THE PAROTID GLAND Adult subjects already enrolled in this protocol and healthy volunteers will be eligible for this research procedure if they fulfill the criteria below and sign the parotid biopsy consent form. Healthy volunteers will be recruited only for the ultrasound guided core needle biospy of the parotid gland. They will sign the parotid biopsy consent form only. INCLUSION CRITERIA: Age 18 years or older. Ability to give informed consent. EXCLUSION CRITERIA: History of bleeding diathesis or the current use of anticoagulants. Any uncontrolled or severe chronic disease.

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, United StatesOuvrir National Institutes of Health Clinical Center, 9000 Rockville Pike dans Google Maps
Terminé1 Centres d'Étude